This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is a firm fixed-price delivery order valued at $9,284.40. The contract was awarded by the Defense Logistics Agency (DLA) and has no set-aside designation. It is part of the DLA's larger SPE2DB Indefinite Delivery Contract (IDC) valued at up to $499,999,999, which allows the agency to issue delivery orders for a comprehensive range of pharmaceutical products to support the medical supply needs of...
This contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is a firm fixed-price delivery order under the Defense Logistics Agency's (DLA) SPE2DB Indefinite Delivery Contract (IDC) valued at $499,999,999. The contract covers a wide range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to support the medical supply needs of military health facilities worldwide. The current...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, is a firm fixed-price delivery order valued at $15,474.00. The contract was awarded by the Defense Logistics Agency (DLA) and has an ultimate completion date of September 18, 2024. DMS Pharmaceutical Group Inc. holds a significant indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to $499,999,999, which runs through December 31, 2025. This...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, was issued by the Defense Logistics Agency (DLA) as a delivery order under the DLA's SPE2DB Indefinite Delivery Contract (IDC) valued at $499,999,999. The award, valued at $98,364.00, is for the provision of Xolair 150 mg/mL syringes to support the medical supply needs of military healthcare facilities. As a key supplier in the federal pharmaceutical supply chain, DMS...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, was issued by the Defense Logistics Agency (DLA) under the Medical Supply Chain division. The $9,671.25 firm fixed-price delivery order is for the pharmaceutical product XOLAIR 150 MG/ML SYRINGEML, with a completion date of June 4, 2024. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the DLA to issue delivery...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, was issued by the Defense Logistics Agency (DLA) as a delivery order under the SPE2DB Indefinite Delivery Contract (IDC) valued at $499,999,999 and valid through November 2026. The contract provides the DLA with a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, was issued by the Defense Logistics Agency (DLA) as a firm fixed-price delivery order under a $499,999,999 Indefinite Delivery Contract (IDC). The contract covers the supply of a diverse range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to support the medical needs of the Department of Defense (DoD)...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is a delivery order under the Defense Logistics Agency's (DLA) SPE2DB program. The $18,612.48 firm fixed-price contract is for the delivery of the pharmaceutical product Xolair 150 mg/mL syringe to support the medical supply needs of Department of Defense (DoD) healthcare facilities. The contract has no set-aside designation and is part of DMS Pharmaceutical Group's broader indefinite delivery contract...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is a delivery order valued at $98,132.40 issued by the Defense Logistics Agency (DLA) under the SPE2DB Indefinite Delivery Contract (IDC). The contract is for the delivery of XOLAIR 150 MG/ML SYRINGEML, a specialized pharmaceutical product. The IDC, valued at $499,999,999, enables the DLA to issue firm fixed-price delivery orders for a wide range of pharmaceutical items to support the medical supply needs...
This contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, is a delivery order valued at $74,275.20 issued under the Defense Logistics Agency's (DLA) SPE2DB Indefinite Delivery Contract. The contract is for the provision of pharmaceutical products, including Xolair 150 mg/1.2 ml powder, to support the medical supply needs of military healthcare facilities. This single-award IDC, valued at $499,999,999, enables the DLA to issue firm fixed-price...